Margetuximab Helps to Delay Disease Progression in Advanced, HER2-positive Breast Cancers, Phase 3 Trial Shows

Margetuximab Helps to Delay Disease Progression in Advanced, HER2-positive Breast Cancers, Phase 3 Trial Shows
A combination of MacroGenics' HER2 antibody margetuximab and standard chemotherapy is superior to Herceptin (trastuzumab) plus chemotherapy at extending the time to disease progression among advanced and pre-treated breast cancer patients whose tumors are positive for HER2 (human epidermal growth factor receptor 2), a Phase 3 trial shows. Specifically, the SOPHIA trial (NCT02492711) included breast cancer patients who had received at least two prior HER2-targeted treatments for their metastatic disease —including Genentech's Herceptin, Perjeta (pertuzumab), and Kadcycla (ado-trastuzumab emtansine) — but no more than three prior treatments in total. “There are currently no approved agents for the treatment of patients with metastatic HER2+ breast cancer who have previously received trastuzumab, pertuzumab and ado-trastuzumab emtansine," Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Comprehensive Cancer Center, said in a press release. "If margetuximab is approved, based on SOPHIA data, I believe that this agent could become a valuable treatment option for these patients.” Treatment for HER2-p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.